Article Information
History
- March 28, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Brooke E. Nichols1,2,*,
- Alexandra de Nooy2,
- Naseem Cassim3,4,
- Lucia Hans3,4,5,
- Manuel Pedro da Silva3,4,
- Kamy Chetty4,
- Kyra H. Grantz2,3,
- Alvin X. Han6,
- Andrew N. Phillips7,
- Lise Jamieson8,9,
- Lesley E. Scott3 and
- Wendy S. Stevens3,4,*
- 1Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
- 2FIND, Geneva, Switzerland
- 3Wits Diagnostic Innovation Hub, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 4National Health Laboratory Service (NHLS), Johannesburg, South Africa
- 5Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa
- 6Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, Netherlands
- 7Institute for Global Health, University College London, London, UK
- 8Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 9The South African Department of Science and Innovation/National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa
- ↵*Correspondence: brooke.nichols{at}finddx.org, wendy.stevens{at}wits.ac.za
Posted March 28, 2024.
The 10-year health impact, economic impact, and return on investment of the South African molecular diagnostics programme for HIV, Tuberculosis and SARS-CoV-2
